资源类型:
期刊
WOS体系:
Article
Pubmed体系:
Journal Article
收录情况:
◇ SCIE
文章类型:
论著
单位:
[1]Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
麻醉科
华中科技大学同济医学院附属同济医院
[2]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
肿瘤科
华中科技大学同济医学院附属同济医院
ISSN:
0006-2952
摘要:
Clinical and preclinical interest in Type 2 diabetes (T2D)-associated cognitive dysfunction (TDACD) has grown in recent years. However, the precise mechanisms underlying TDACD need to be further elucidated. Ferroptosis was reportedly involved in neurodegenerative diseases and diabetes-related organ injuries; however, its role in TDACD remains elusive. In this study, mice fed with a high-fat-diet combined with streptozotocin (HFD-STZ) were used as a T2D model to assess the role of ferroptosis in cognitive dysfunction. We found that ferroptosis was mainly activated in hippocampal neurons but not in microglia or astrocytes. Accordingly, increased levels of transferrin receptor and decreased levels of ferritin, GPX4, and SLC7A11 were observed in hippocampal neurons. In addition, pre-treatment with liproxstatin-1, a ferroptosis inhibitor, attenuated iron accumulation and oxidative stress response, which resulted in improved cognitive function in the HFD-STZ group. Furthermore, we found that p-AMP-activated protein kinase (AMPK) was decreased in the HFD-STZ group. Pre-treatment with AMPK agonist increased the expression of AMPK and GPX4, but decreased lipocalin 2 (LCN2) in the hippocampus that resulted in improved spatial learning ability in the HFD-STZ group. Taken together, we found that activation of neuronal ferroptosis in the hippocampus contributed to cognitive impairment of HFD-STZ mice. Furthermore, AMPK activation may reduce hippocampal ferroptosis, and consequently improve cognitive performance in diabetic mice.Copyright © 2022 Elsevier Inc. All rights reserved.
基金:
National Natural Science Foundation of China [grant numbers 81974160, 82171266] and National Key R&D Program of China (program number 2020YFC2009002).
被引次数:
14
WOS:
WOS:000898516800001
PubmedID:
36502872
中科院(CAS)分区:
出版当年[2022]版:
大类
|
2 区
医学
小类
|
2 区
药学
最新[2025]版:
大类
|
2 区
医学
小类
|
2 区
药学
JCR分区:
出版当年[2021]版:
Q1
PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1
PHARMACOLOGY & PHARMACY
影响因子:
5.3
最新[2023版]
5.2
最新五年平均
6.1
出版当年[2021版]
6.194
出版当年五年平均
5.858
出版前一年[2020版]
5.8
出版后一年[2022版]
第一作者:
Xie Zheng
第一作者单位:
[1]Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
通讯作者:
Luo Ailin;Li Shiyong
推荐引用方式(GB/T 7714):
Xie Zheng,Wang Xuan,Luo Xiaoxiao,et al.Activated AMPK mitigates diabetes-related cognitive dysfunction by inhibiting hippocampal ferroptosis[J].BIOCHEMICAL PHARMACOLOGY.2023,207:115374.doi:10.1016/j.bcp.2022.115374.
APA:
Xie Zheng,Wang Xuan,Luo Xiaoxiao,Yan Jing,Zhang Jie...&Li Shiyong.(2023).Activated AMPK mitigates diabetes-related cognitive dysfunction by inhibiting hippocampal ferroptosis.BIOCHEMICAL PHARMACOLOGY,207,
MLA:
Xie Zheng,et al."Activated AMPK mitigates diabetes-related cognitive dysfunction by inhibiting hippocampal ferroptosis".BIOCHEMICAL PHARMACOLOGY 207.(2023)